OPKO Health (NASDAQ:OPK) Earns Outperform Rating from Barrington Research

OPKO Health (NASDAQ:OPK)‘s stock had its “outperform” rating restated by equities research analysts at Barrington Research in a note issued to investors on Wednesday,Benzinga reports. They presently have a $2.25 price objective on the biotechnology company’s stock. Barrington Research’s price objective would suggest a potential upside of 30.81% from the company’s current price.

Several other research analysts also recently commented on OPK. HC Wainwright reaffirmed a “buy” rating and set a $3.00 target price on shares of OPKO Health in a report on Monday, March 3rd. StockNews.com raised OPKO Health from a “sell” rating to a “hold” rating in a research note on Monday, March 3rd.

OPKO Health Stock Performance

OPKO Health stock opened at $1.72 on Wednesday. The business has a 50 day moving average of $1.61 and a 200-day moving average of $1.57. The company has a market capitalization of $1.16 billion, a P/E ratio of -9.05 and a beta of 1.70. OPKO Health has a 1 year low of $0.86 and a 1 year high of $2.04. The company has a debt-to-equity ratio of 0.30, a current ratio of 2.97 and a quick ratio of 2.69.

OPKO Health (NASDAQ:OPK) last announced its quarterly earnings results on Thursday, February 27th. The biotechnology company reported $0.01 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.08) by $0.09. The firm had revenue of $183.60 million during the quarter, compared to analysts’ expectations of $155.42 million. OPKO Health had a negative net margin of 18.65% and a negative return on equity of 9.76%. On average, equities research analysts predict that OPKO Health will post -0.25 earnings per share for the current year.

Insiders Place Their Bets

In related news, CEO Phillip Md Et Al Frost acquired 150,000 shares of OPKO Health stock in a transaction dated Friday, January 17th. The stock was bought at an average price of $1.47 per share, with a total value of $220,500.00. Following the transaction, the chief executive officer now directly owns 213,186,477 shares in the company, valued at $313,384,121.19. This represents a 0.07 % increase in their position. The purchase was disclosed in a filing with the SEC, which is available at the SEC website. In the last ninety days, insiders acquired 764,971 shares of company stock worth $1,145,692. Company insiders own 47.26% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of OPK. Rubric Capital Management LP increased its stake in OPKO Health by 9.6% in the third quarter. Rubric Capital Management LP now owns 48,706,640 shares of the biotechnology company’s stock valued at $72,573,000 after purchasing an additional 4,284,336 shares in the last quarter. Millennium Management LLC grew its stake in shares of OPKO Health by 85.3% in the 4th quarter. Millennium Management LLC now owns 4,588,526 shares of the biotechnology company’s stock valued at $6,745,000 after buying an additional 2,112,382 shares during the period. Lazard Asset Management LLC increased its position in OPKO Health by 143.6% in the 4th quarter. Lazard Asset Management LLC now owns 2,548,667 shares of the biotechnology company’s stock valued at $3,746,000 after buying an additional 1,502,342 shares in the last quarter. Altshuler Shaham Ltd acquired a new position in OPKO Health during the 4th quarter worth approximately $2,082,000. Finally, Norges Bank acquired a new position in OPKO Health during the 4th quarter worth approximately $1,657,000. Institutional investors and hedge funds own 64.63% of the company’s stock.

OPKO Health Company Profile

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.